Wealth Enhancement Advisory Services
ESPR

Wealth Enhancement Advisory Services’s Esperion Therapeutics ESPR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$4.2K – 2642
2024
Q1 		$4.2K Buy
+10,000
New +$24.3K ﹤0.01% 2435

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Wealth Enhancement Advisory Services's ESPR Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Esperion Therapeutics (ESPR) stake by 49% in Q2 2026, selling an estimated $32.6K and leaving 12,321 shares worth $39.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3954.

Wealth Enhancement Advisory Services first reported a position in ESPR in Q1 2024 and has held it in 8 quarters since. The position peaked at $105K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Wealth Enhancement Advisory Services held 12,321 shares of Esperion Therapeutics worth $39.2K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 11,647 Esperion Therapeutics shares in Q2 2026, an estimated $32.6K.
  • Esperion Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3954 holding.
  • Wealth Enhancement Advisory Services first reported a position in Esperion Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Wealth Enhancement Advisory Services's Esperion Therapeutics position peaked at $105K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.